Incanthera PLC Appointment of Company Secretary (9914W)
29 Aprile 2021 - 8:00AM
UK Regulatory
TIDMINC
RNS Number : 9914W
Incanthera PLC
29 April 2021
29 April 2021
Incanthera plc
("Incanthera" or the "Company")
Appointment of Company Secretary
Incanthera plc (AQSE: INC), the specialist oncology company
focused on innovative technologies in oncology and dermatology is
pleased to announce the appointment of Suzanne Brocks to Company
Secretary with effect from 28(th) April 2021.
Suzanne joined Incanthera in 2014 as Head of Communications, a
role she has held prior to and during the Company's flotation on to
the AQSE Growth Market, and she will continue to hold this role in
addition to her appointment as Company Secretary.
In addition to public and investor relations, Suzanne has been
significantly involved in the administrative affairs of the Company
including the coordination of statutory and regulatory matters. The
position as Company Secretary will reflect her involvement across
these areas of the Company, in complement to her role overseeing
internal and public facing corporate communications.
The Company is delighted Suzanne has accepted this position and
wishes her well in her enhanced role.
For further enquiries:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis/Mark Rogers +44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/Tom Price/John Howes/Bob
Pountney +44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on
transforming cancer treatment by creating environments in which
cancer cannot survive. It seeks to identify and develop innovative
solutions to current clinical, commercially relevant unmet needs,
utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. This has achieved
proof of concept and the Company is now focussed upon delivering
Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in the
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
@incantheraplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXDBGDSGSDDGBI
(END) Dow Jones Newswires
April 29, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Apr 2023 a Apr 2024
